BAUSCH + LOMB CORP (BLCO)

BLCO Stock Earnings: Bausch & Lomb Meets EPS, Misses Revenue for Q1 2024

BLCO stock results show that Bausch & Lomb met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Bausch + Lomb Announces First-Quarter 2024 Results

Bausch + Lomb Announces Presentation of New Data at the Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb Announces Statistically Significant Results From a Clinical Study of a Novel Daily Nutritional Supplement for Dry Eyes

Oversold Conditions For Bausch + Lomb (BLCO)

Bausch + Lomb Reports More Than 84 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through Innovative Recycling Programs

Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1

BLCO Crosses Above Key Moving Average Level

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

Bausch + Lomb stock gains after Q4 earnings beat (NYSE:BLCO)

Bausch + Lomb (BLCO) exceeds Q4 2023 expectations and predicts strong financial performance for 2024 with revenue exceeding forecasts. Read more here.

Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

Bausch + Lomb Non-GAAP EPS of $0.24 beats by $0.07, revenue of $1.17B beats by $70M (NYSE:BLCO)

Bausch + Lomb reports Q4 results: Non-GAAP EPS of $0.24 beats estimates by $0.07, while revenue of $1.17B beats expectations by $70M.

Bausch + Lomb Announces Fourth-Quarter and Full-Year 2023 Results and Provides 2024 Guidance

Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21

Bausch + Lomb stock downgraded at J.P. Morgan (NYSE:BLCO)

J.P. Morgan downgrades eyecare company Bausch + Lomb (BLCO) due to risks related to its planned spinoff from parent company Bausch Health (BHC). Read more here.

Bausch + Lomb stock drops amid comments at JPMorgan Healthcare Conference

Bausch + Lomb shares decline after executives reveal plans for 2024 to be an investment year, impacting investor sentiment.

Bausch Health stock gains after an appeals hearing in Norwich case over generic Xifaxan

Bausch Health's shares rise after appeals hearing in patent case over Xifaxan, with positive litigation updates potentially leading to a BLCO spin.

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Bausch + Lomb to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Bausch + Lomb Reports More Than 76 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

Bausch + Lomb Non-GAAP EPS of $0.22 beats by $0.03, revenue of $1B beats by $9.86M (NYSE:BLCO)

Bausch + Lomb announces strong Q3 results, beating earnings and revenue expectations.

Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance

Bringing Back an Ex-CEO Rarely Restores Market Values

When Dollar General Corp. brought back Todd Vasos for a second stint at the top earlier this month, it became just the latest struggling household name to try to fix its problems by reappointing a successful former chief executive officer.